Why Amgen Stock Edged Past the Market on Thursday

By Eric Volkman | November 13, 2025, 5:36 PM

Key Points

The stock of pharmaceutical company Amgen (NASDAQ: AMGN) didn't exactly have a banner trading session on Thursday. In closing the day nearly flat, however, to notch a slight beat on the S&P 500 (SNPINDEX: ^GSPC). The benchmark indicator slumped by almost 1.7% on Thursday. Amgen was mentioned positively by two pundits that morning.

Talk is cheap

The first of the two was a well-known name in stock prognostication.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »

Person checking the shelves of a pharmacy.

Image source: Getty Images.

In Jim Cramer's "Stop Trading" segment on CNBC's Squawk on the Street program, the famous stock picker mentioned Amgen positively. He pointed to the very encouraging results of a recent phase 3 clinical trial of its cholesterol drug Repatha. The medication was shown to significantly reduce the risk of heart attack and stroke in the study.

Separately, on Wednesday shortly after market close, Scotiabank analyst Louis Chen initiated coverage of Amgen stock. Chen rates it a sector outperform (buy, in other words) at a price target of $385 per share.

Justifiable reaction

I feel the Repatha news, exciting though it may be, is now fully priced into its maker's stock. I like Amgen as an investment personally, but I don't think the bullish musings of two analysts should have led to any kind of bull run. The market's Thursday treatment of the shares feels proper and correct.

Should you invest $1,000 in Amgen right now?

Before you buy stock in Amgen, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Amgen wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $624,230!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,187,967!*

Now, it’s worth noting Stock Advisor’s total average return is 1,069% — a market-crushing outperformance compared to 195% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of November 10, 2025

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amgen. The Motley Fool recommends Bank Of Nova Scotia. The Motley Fool has a disclosure policy.

Mentioned In This Article

Latest News